LEADER 03952nam  22006735  450 
001 9910899893503321
005 20251113211957.0
010   $a981-9773-80-6
024 7 $a10.1007/978-981-97-7380-0
035   $a(MiAaPQ)EBC31741938
035   $a(Au-PeEL)EBL31741938
035   $a(CKB)36410323700041
035   $a(DE-He213)978-981-97-7380-0
035   $a(EXLCZ)9936410323700041
100   $a20241026d2024      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAngiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers $eA Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview /$fedited by Mukesh Nandave
205   $a1st ed. 2024.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2024.
215   $a1 online resource (609 pages)
311 08$a981-9773-79-2 
320   $aIncludes bibliographical references.
327   $aChapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS) -- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders -- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs) -- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin?angiotensin system -- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients -- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure -- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients -- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease -- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients -- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.
330   $aThe auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
606   $aPharmacology
606   $aPharmacovigilance
606   $aMedicine$xResearch
606   $aBiology$xResearch
606   $aClinical biochemistry
606   $aTherapeutics
606   $aPharmacology
606   $aDrug Safety and Pharmacovigilance
606   $aBiomedical Research
606   $aMedical Biochemistry
606   $aTherapeutics
615  0$aPharmacology.
615  0$aPharmacovigilance.
615  0$aMedicine$xResearch.
615  0$aBiology$xResearch.
615  0$aClinical biochemistry.
615  0$aTherapeutics.
615 14$aPharmacology.
615 24$aDrug Safety and Pharmacovigilance.
615 24$aBiomedical Research.
615 24$aMedical Biochemistry.
615 24$aTherapeutics.
676   $a616.1061
700   $aNandave$b Mukesh$01737180
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910899893503321
996   $aAngiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers$94213941
997   $aUNINA